HPR87 A Review and Analysis of Medicines Following the Innovative Licensing and Access Pathway (ILAP) in the UK: Does the Pathway Lead to Faster Regulatory Approval and HTA Recommendation?
Abstract
Authors
Y Elsakary B Connelly H Scrutton D Finocchiaro A Heathfield MW Bending